Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Key Points

• Insider sale: Director Blake Borgeson sold 30,000 Recursion Pharmaceuticals shares for $97,500 under a pre-arranged Rule 10b5-1 plan, reducing his position by 0.48% to 6.19 million shares. He also sold 40,000 shares in July and 30,000 in June.
• Quarterly results missed estimates: Recursion reported a $0.25-per-share loss versus the $0.24 consensus estimate, while revenue of $7.67 million fell well short of the $10.97 million forecast. The company remains deeply unprofitable, with a negative net margin exceeding 800%.
• Mixed investor outlook: Analysts’ average rating is “Hold,” with an $8.10 price target compared with the stock’s recent price near $3.18. Despite financial losses, institutional investors own 89.06% of the company and several major funds increased their stakes.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total value of $97,500.00. Following the sale, the director owned 6,188,287 shares of the company's stock, valued at approximately $20,111,932.75. The trade was a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.96, for a total value of $158,400.00.
• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.68, for a total transaction of $110,400.00.

Recursion Pharmaceuticals Stock Up 0.3%

Recursion Pharmaceuticals stock traded up $0.01 during mid-day trading on Thursday, hitting $3.18. The company had a trading volume of 14,782,481 shares, compared to its average volume of 18,481,574. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18. The business has a fifty day moving average of $3.33 and a 200 day moving average of $3.47. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -2.65 and a beta of 1.03.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $10.97 million. During the same quarter in the prior year, the firm posted ($0.41) EPS. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -0.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. JPMorgan Chase & Co. cut their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating on the stock in a research report on Thursday, April 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Finally, Morgan Stanley boosted their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an "equal weight" rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.10.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company's stock worth $192,998,000 after acquiring an additional 7,407,606 shares during the period. State Street Corp boosted its holdings in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company's stock valued at $103,616,000 after acquiring an additional 7,064,963 shares in the last quarter. Norges Bank acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $23,473,000. ARK Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock worth $152,626,000 after acquiring an additional 3,771,357 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Recursion Pharmaceuticals during the first quarter worth about $7,370,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals News Summary

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Genentech collaboration advanced: Genentech opted to move the partnership’s first neuroscience target into a joint early-discovery program. This is an early validation of Recursion’s AI-enabled drug-discovery platform and could support future collaboration economics. Recursion Reports Second Quarter Financial Results
• Positive Sentiment: Pipeline milestones continue: REC-7735 received IND clearance, with its Phase 1/2 ZINNIA study expected to begin in the second half of 2026. Recursion also expects additional Phase 2 data for REC-4881 in November, while other clinical programs remain on schedule. Recursion Reports Second Quarter Financial Results
• Positive Sentiment: Spending outlook improved: Recursion outlined approximately $375 million in 2026 cash operating expenses, indicating continued cost discipline as it advances its clinical pipeline. Recursion Outlines 2026 Cash Operating Expense Guidance
• Neutral Sentiment: Loss narrowed year over year: Second-quarter loss improved to $0.25 per share from $0.41 a year earlier, but Recursion remains deeply unprofitable. Investors are likely to focus on whether pipeline progress can eventually translate into recurring revenue.
• Negative Sentiment: Quarterly results missed expectations: Recursion reported a loss of $0.25 per share versus the $0.24 consensus estimate, while revenue fell to $7.67 million from $19.22 million a year earlier and missed estimates of approximately $10.97 million. The decline was primarily linked to lower collaboration revenue, weighing on the near-term earnings outlook. RXRX Q2 Earnings Miss Estimates
• Negative Sentiment: Valuation remains a concern: Despite the company’s long-term platform potential, analysts and market commentary continue to view RXRX as expensive relative to its current revenue base, ongoing losses and sharply negative margins. Recursion Pharmaceuticals Stock Still Looks Expensive

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source